COMP <GO>
DMAC vs ARVN // REVENUE GROWTH (YOY)
DiaMedica Therapeutics Inc. (NASDAQ) VS. Arvinas Inc. (NASDAQ) • 15-METRIC TALLY: DMAC 1
— ARVN 3
■ METRIC PARITY
LAST: $9.52 (-3.05%) • MKT CAP: $513.4M
revenue-growth
—
LAST: $7.90 (+3.95%) • MKT CAP: $516.6M
revenue-growth
-0.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DMAC VS. ARVN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DMAC | ARVN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -32.10% | -2.90 | ARVN | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.67% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -45.10% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -30.80% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | — | -0.30% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | ARVN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.0 | 54.6 | +8.46 | DMAC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $513.4M | $516.6M | -$3.2M | ARVN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DMAC REV | ARVN REV | DMAC GROSS % | ARVN GROSS % | DMAC FCF | ARVN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $262.6M | — | — | -$29.1M | -$275.7M |
| FY 2024 | $0 | $263.4M | — | — | -$22.1M | -$261.1M |
| FY 2023 | $0 | $78.5M | — | — | -$18.7M | -$347.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DMAC // BETA —
ARVN // BETA —